Respiri Launches Wheezo Device and App in US Market –


Australian digital health company Respiri has deployed its Wheezo device, app and healthcare monitoring portal at Michigan Children’s Hospital, the technology’s first US customer.

Software as a Service (SaaS) platform is used to detect wheezing, a typical symptom of asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases, giving an objective measure of obstruction respiratory tract.

After a pilot phase, the Wheezo system – which was approved by the FDA last year – has now been integrated into Access Telehealth Remotli’s remote patient monitoring platform in Michigan, and is expected to be used by the first patients. Americans in the coming weeks.

The rollout will focus on children with asthma with the aim of reducing exacerbations and hospitalizations, improving patient outcomes and reducing healthcare costs, with the entire system being reimbursable. Access is currently working on integration work with Michigan’s electronic medical record (EMR) system.

Respiri states (PDF) that monitoring and maintaining irregular breathing patterns in patients with respiratory disease is currently lacking in the United States.

In asthma, for example, the current standard of care relies on questionnaires based on patient recall and responses, and can yield subjective results. Meanwhile, other tests such as spirometry to test lung function are not user friendly as they require forced breathing and can be difficult to administer to children and the elderly.

Using wheezing, patients record 30 seconds of normal breathing with the device placed against the trachea, which Respiri says is enough to provide an objective assessment of wheezing that can help diagnose conditions. and guide treatment.

The mobile app helps patients manage their asthma by tracking symptoms, triggers, medication use, and environmental factors that may affect their condition, such as pollen and pollution levels.

In a recent company update, Respiri said it had decided to look to the US market as Australia “has a long way to go” when it comes to adopting patient monitoring. remotely, while the United States already has a defined reimbursement framework in place.

Edison analysts said the first U.S. installation is a significant milestone for Respiri, as the need to implement new systems “has always been a major barrier to bringing new services into hospitals and health care providers”.

“We are awaiting feedback from the first patient access at Michigan Children’s Hospital to lay the foundation for further adoption of the product and associated services,” Edison’s Soo Romanoff and Jyotli Prakash said in a customer update.

“We note that Detroit, the location of Children’s Hospital, is home to more than 70,000 children with asthma and that the hospital offers many outpatient asthma services, providing a strong launch pad for Respiri releases his device.”


Comments are closed.